Journal
IMMUNITY INFLAMMATION AND DISEASE
Volume 9, Issue 1, Pages 128-133Publisher
WILEY
DOI: 10.1002/iid3.367
Keywords
-
Categories
Funding
- Delegation of the European Union in Gabon, Sao Tome and Principe
- ECCAS
- CHU-Mere-Enfant
- Fondation Jeanne EBORI
Ask authors/readers for more resources
The study found that some individuals have pre-existing humoral cross-reactive immunity to SARS-CoV-2, which is crucial for further investigation and vaccine research related to the virus.
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged throughout the world. Building knowledge around Covid-19 is crucial to devise facts based approaches to respond efficiently against this pandemic. Aim: We aimed to investigate pre-existing humoral cross-reactive immunity to SARS-CoV-2. Method: We have tested the reactivity against SARS-CoV-2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS-CoV-2 N-antigen using a well-validated serological platform; Elecsys assay. Results: Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS-CoV-2 N-antigen, suggesting the presence of anti-SARS-CoV-2 N-antigen antibodies. Conclusion: Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available